ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
96.05
-0.74 (-0.76%)
Sep 22, 2025, 3:51 PM EDT - Market open
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover ANI Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $89.88, which forecasts a -6.42% decrease in the stock price over the next year. The lowest target is $68 and the highest is $121.
Price Target: $89.88 (-6.42%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $93 → $121 | Strong Buy | Maintains | $93 → $121 | +25.98% | Sep 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $86 → $114 | Strong Buy | Maintains | $86 → $114 | +18.69% | Sep 8, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $65 → $77 | Hold | Maintains | $65 → $77 | -19.83% | Aug 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $84 → $93 | Strong Buy | Maintains | $84 → $93 | -3.18% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $84 | Strong Buy | Initiates | $84 | -12.55% | Jul 10, 2025 |
Financial Forecast
Revenue This Year
856.21M
from 614.38M
Increased by 39.36%
Revenue Next Year
937.14M
from 856.21M
Increased by 9.45%
EPS This Year
7.37
from -1.04
EPS Next Year
8.04
from 7.37
Increased by 9.13%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 896.6M | 1.0B | |||
| Avg | 856.2M | 937.1M | |||
| Low | 813.2M | 875.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.9% | 21.5% | |||
| Avg | 39.4% | 9.5% | |||
| Low | 32.4% | 2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.73 | 9.24 | |||
| Avg | 7.37 | 8.04 | |||
| Low | 6.93 | 7.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 25.3% | |||
| Avg | - | 9.1% | |||
| Low | - | -3.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.